文献速递物质与行为成瘾

曲马多缓释剂用于阿片戒断的随机临床试验

Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
PubMed 文献 · JAMA Psychiatry · 2017-01-01

在这项纳入103例阿片使用障碍患者的随机临床试验中,患者经吗啡稳定后分别接受可乐定、曲马多缓释剂或丁丙诺啡7天递减,曲马多缓释剂在减少戒断症状方面优于可乐定、与丁丙诺啡相当。

要点

  • 曲马多缓释剂减少阿片戒断症状的效果优于可乐定,与丁丙诺啡相当。
  • 丁丙诺啡组递减期末保留率显著高于可乐定组,曲马多缓释剂组居中且无显著差异。
  • 曲马多缓释剂组与可乐定组在递减至递减后阶段SOWS总分显著下降,丁丙诺啡组无显著下降。

核心结论

  • 曲马多缓释剂在住院递减方案中减少阿片戒断症状的效果优于可乐定,与丁丙诺啡相当。
  • 数据支持进一步研究曲马多缓释剂作为管理阿片戒断症状的方法。

研究设计与样本

  • 随机临床试验,在住院研究环境中纳入103例阿片使用障碍患者。
  • 患者先接受吗啡30 mg皮下注射每日4次稳定治疗,随后7天递减期随机接受可乐定(n=36)、曲马多缓释剂(n=36)或丁丙诺啡(n=31),递减后交叉至双盲安慰剂。
  • 研究时间为2010年10月25日至2015年6月23日。

主要发现

  • 103例参与者中88例(85.4%)为男性,43例(41.7%)为白人,平均(SD)年龄28.9(10.4)岁。
  • 递减期末保留率:丁丙诺啡组28例(90.3%)显著高于可乐定组22例(61.1%);曲马多缓释剂组26例(72.2%)居中且与其他组无显著差异(χ2=8.5,P=.01)。
  • COWS评分显示阶段效应显著(递减期均值5.19[SE,.26];递减后均值3.97[SE,.23];F2,170=3.6,P=.03),SOWS评分阶段效应显著(递减期均值8.81[SE,.40];递减后均值4.14[SE,.30];F2,170=15.7,P<.001),但无组间效应或组×阶段交互作用。
  • SOWS总分曲线下面积分析显示递减期至递减后戒断严重度显著下降(F2,159=17.7,P<.001):可乐定组(递减期均值13.1;递减后均值3.2;P<.001)和曲马多缓释剂组(递减期均值7.4;递减后均值2.8;P=.03),丁丙诺啡组无显著下降(递减期均值6.4;递减后均值7.4)。
  • 伴随用药使用从稳定期至递减期在可乐定组(稳定期均值0.64[SE,.05];递减期均值1.54[SE,.10];P<.001)和曲马多缓释剂组(稳定期均值0.53[SE,.05];递减期均值1.19[SE,.09];P=.003)显著增加,从稳定期至递减后在丁丙诺啡组显著增加(稳定期均值0.46[SE,.05];递减后均值1.17[SE,.09];P=.006)。

关键数值与推荐

  • 递减期末保留率:丁丙诺啡90.3% vs 可乐定61.1%,差异显著(χ2=8.5,P=.01)。
  • SOWS总分曲线下面积递减期至递减后下降:可乐定P<.001,曲马多缓释剂P=.03,丁丙诺啡无显著下降。
  • 纳曲酮选择比例组间无显著差异(χ2=2.5,P=.29)。

临床怎么用

  • 曲马多缓释剂可作为阿片戒断症状管理的可选方案,尤其适用于可乐定效果不足时。
  • 丁丙诺啡在递减期保留率方面可能更具优势,但需结合患者具体情况选择。
  • 戒断期间需监测伴随用药使用变化,其增加可能提示戒断症状加重。

局限性

  • 研究在住院研究环境中进行,结果外推至门诊或社区场景需谨慎。
  • 样本量有限(103例),部分亚组分析效能可能不足。
  • 纳曲酮诱导为自愿选择,选择偏倚可能影响该结局解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Opioid use disorder (OUD) is a significant public health problem. Supervised withdrawal (ie, detoxification) from opioids using clonidine or buprenorphine hydrochloride is a widely used treatment. OBJECTIVE: To evaluate whether tramadol hydrochloride extended-release (ER), an approved analgesic with opioid and nonopioid mechanisms of action and low abuse potential, is effective for use in supervised withdrawal settings. DESIGN, SETTING, AND PARTICIPANTS: A randomized clinical trial was conducted in a residential research setting with 103 participants with OUD. Participants' treatment was stabilized with morphine, 30 mg, administered subcutaneously 4 times daily. A 7-day taper using clonidine (n = 36), tramadol ER (n = 36), or buprenorphine (n = 31) was then instituted, and patients were crossed-over to double-blind placebo during a post-taper period. The study was conducted from October 25, 2010, to June 23, 2015. MAIN OUTCOMES AND MEASURES: Retention, withdrawal symptom management, concomitant medication utilization, and naltrexone induction. Results were analyzed over time and using area under the curve for the intention-to-treat and completer groups. RESULTS: Of the 103 participants, 88 (85.4%) were men and 43 (41.7%) were white; mean (SD) age was 28.9 (10.4) years. Buprenorphine participants (28 [90.3%]) were significantly more likely to be retained at the end of the taper compared with clonidine participants (22 [61.1%]); tramadol ER retention was intermediate and did not differ significantly from that of the other groups (26 [72.2%]; χ2 = 8.5, P = .01). Time-course analyses of withdrawal revealed significant effects of phase (taper, post taper) for the Clinical Opiate Withdrawal Scale (COWS) score (taper mean, 5.19 [SE, .26]; post-taper mean, 3.97 [SE, .23]; F2,170 = 3.6, P = .03) and Subjective Opiate Withdrawal Scale (SOWS) score (taper mean,8.81 [SE, .40]; post-taper mean, 4.14 [SE, .30]; F2,170 = 15.7, P < .001), but no group effects or group × phase interactions. Analyses of area under the curve of SOWS total scores showed significant reductions (F2,159 = 17.7, P < .001) in withdrawal severity between the taper and post-taper periods for clonidine (taper mean, 13.1; post-taper mean, 3.2; P < .001) and tramadol ER (taper mean, 7.4; post-taper mean, 2.8; P = .03), but not buprenorphine (taper mean, 6.4; post-taper mean, 7.4). Use of concomitant medication increased significantly (F2,159 = 30.7, P < .001) from stabilization to taper in the clonidine (stabilization mean, 0.64 [SE, .05]; taper mean, 1.54 [SE, .10]; P < .001) and tramadol ER (stabilization mean, 0.53 [SE, .05]; taper mean, 1.19 [SE, .09]; P = .003) groups and from stabilization to post taper in the buprenorphine group (stabilization mean, 0.46 [SE, .05] post-taper mean, 1.17 [SE, .09]; P = .006), suggesting higher withdrawal for those groups during those periods. Naltrexone initiation was voluntary and the percentage of participants choosing naltrexone therapy within the clonidine (8 [22.2%]), tramadol ER (7 [19.4%]), or buprenorphine (3 [9.7%]) groups did not differ significantly (χ2 = 2.5, P = .29). CONCLUSIONS AND RELEVANCE: The results of this trial suggest that tramadol ER is more effective than clonidine and comparable to buprenorphine in reducing opioid withdrawal symptoms during a residential tapering program. Data support further examination of tramadol ER as a method to manage opioid withdrawal symptoms. TRIAL REGISTRATION: Clinicaltrials.gov Identifier: NCT01188421.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Dunn KE, Tompkins DA, Bigelow GE, et al. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial. JAMA Psychiatry. 2017. PMID: 28700791. doi:10.1001/jamapsychiatry.2017.1838

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。